Free Post Earnings Research Report: QIAGEN’s Net Sales Rose 8%; Adjusted EPS Advanced 10%

Stock Monitor: National Research Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors.com has just released a free earnings report on QIAGEN N.V. (NYSE: QGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=QGEN. QIAGEN reported its fourth quarter and fiscal 2017 operating and financial results on January 31, 2018. The diagnostic product’s maker outperformed top- and bottom-line expectations and provided guidance for the full year 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for National Research Corporation (NASDAQ: NRCIB), which also belongs to the Services sector as the Company QIAGEN. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=NRCIB

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, QIAGEN most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=QGEN

Earnings Highlights and Summary

Net sales rose 8% to $396.9 million in Q4 2017 compared to net sales of $366.5 million in Q4 2016, representing 5% constant exchange rate (CER) growth, aided by approximately three percentage points due to positive currency movements against the US dollar. The Company’s adjusted net sales including all revenues from the acquisition of OmicSoft (January 2017) rose 6% CER on a y-o-y basis. QIAGEN’s reported numbers exceeded analysts’ expectations of $394.5 million.

During Q4 2017, QIAGEN’s operating income was $43.4 million compared to $4.2 million in Q4 2016. The Company’s reported quarter results included a pre-tax charge of $31.5 million for the settlement of US litigations, while the year-ago same period included a pre-tax restructuring charge of $68.2 million taken for the efficiency program initiated in 2016. QIAGEN’s adjusted operating income grew 8% to $121.7 million in Q4 2017 from $112.7 million in Q4 2016.

Net loss attributable to QIAGEN was $39.7 million, or $0.18 per share, in Q4 2017 compared to net income of $8.6 million, or $0.04 per share, in Q4 2016. The Company’s reported quarter results included an after-tax charge of $0.45 per share primarily as a consequence of the new US tax legislation. QIAGEN’s adjusted net income was $100.1 million, or $0.43 per share, in Q4 2017 compared to $93.5 million, or $0.39 per share, in Q4 2016. The Company’s earnings beat Wall Street’s estimates of $0.42 per share.

For full year (FY) 2017, QIAGEN’s net sales grew 6% to $1.42 billion compared to $1.34 billion in FY16, while adjusted net sales including the OmicSoft acquisition also rose 6% CER to $1.42 billion.

For FY17, net income attributable to QIAGEN was $40.4 million, or $0.17 per share, compared to $80.4 million, or $0.34 per share, in FY 2016. FY17 results included the after-tax charge of $104.4 million primarily for the revaluation of deferred taxes and other tax provisions. The Company’s adjusted net income was $295.3 million, or $1.27 per share, for FY17, an increase from $264.8 million, or $1.11 per share, for FY16.

Balance sheet and cash flows

On December 31, 2017, QIAGEN’s cash and cash equivalents increased to $657.7 million from $439.2 million at December 31, 2016.

The Company’s net cash provided by operating activities was $286.8 million in FY17, down from $341.6 million in FY16, with FY17 results impacted by $41 million in litigation settlements and $48.0 million in restructuring payments. QIAGEN’s free cash flow for FY17 was $196.7 million, down from $267.1 million in FY16.

QIAGEN announced a new commitment to return $200 million to shareholders via open-market repurchases. Shares will be repurchased on the Frankfurt Stock Exchange.

Outlook

For full-year 2018, QIAGEN is forecasting organic net sales growth to be approximately 6% to 7% on CER and total adjusted net sales growth of around 6% to 7% on CER is expected.

For full-year 2018, QIAGEN expects underlying growth in adjusted EPS to approximately $1.38 to $1.40 CER. The Company is estimating underlying growth in adjusted EPS to be reduced to approximately $1.31 to 1.33 CER due to dilution of about $0.03 CER due to US tax reform and an adjusted tax rate of about 20% to 21% for FY18, anticipated dilution of about $0.05 per share for commercialization and development of the QIAstat-Dx system, and accretion of approximately $0.01 per share from the $200 million share repurchase plan.

Stock Performance Snapshot

February 15, 2018 – At Thursday’s closing bell, QIAGEN’s stock rose 2.33%, ending the trading session at $33.80.

Volume traded for the day: 803.87 thousand shares.

Stock performance in the last month – up 2.77%; previous three-month period – up 9.56%; past twelve-month period – up 16.67%; and year-to-date – up 9.28%

After yesterday’s close, QIAGEN’s market cap was at $7.83 billion.

Price to Earnings (P/E) ratio was at 86.89.

The stock is part of the Services sector, categorized under the Research Services industry. This sector was up 0.9% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 489485